CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia
Key facts
- Who runs it
- University Hospital, Tours
- Where
- France2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 100 people, planned
- Started
- 2 Dec 2025
- Expected to end
- Dec 2028
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Caspofungin Acetate 50 MG
- Physiologic saline
- Record updated
- 9 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Male and female ≥18 years
- Medical management of Pneumocystis pneumonia based on :; Microbiological diagnosis of Pneumocystis pneumonia; Respiratory support (oxygen therapy or ventilatory assistance); Systemic co-trimoxazole therapy or systemic second-line anti-Pneumocystis salvage therapy (switch to another anti-Pneumocystis drug is possible, but should be notified) (initiated within 48 hours or less before enrolment)
- Person affiliated to a French social security system or equivalent
- Written informed consent obtained from the participant or, if the patient is not able to give consent from representative (trusted person, family member) or if the delay in obtaining the consent is assumed not compatible with the enrollment requirements, a temporary approval can be obtained from the investigator. In all cases, the patient's written informed consent will have to be obtained as soon as possible; Non-inclusion criteria:
- Persons covered by articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial or administrative decision, minors, and persons subject to a legal protection measure: guardianship or trusteeship). Pregnancy test to be performed in all women from 15 to 45 years old who have not had an ovariectomy
- Other indication(s) for systemic administration of an echinocandin drug
- Known allergy to echinocandin drugs
- Absolute contraindication to aerosol therapy
- Concomitant co-infection at time of diagnosis (except HIV infection)
- Severe liver impairment (i.e. documented severe liver cirrhosis (Child C), or Factor-V protein < 50% and/or INR for prothrombin time of blood coagulation > 1.5)
- history of toxic epidermal necrosis (TEN) and Steven-Johnson syndrome (SJS)
- Participation in other pharmacological study that focuses on echinocandins and/or anti-infectious aerosol therapy or other anti-pneumocystis treatment
- Participation in a trial with an investigational product known to have pulmonary toxicity or of which the safety is not known
This trial is currently available in France.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To assess the efficacy of administrating daily caspofungin aerosols versus placebo for seven days, in adjunction of conventional systemic antifungal therapy during curative treatment of Pneumocystis pneumonia, on the clinical outcome at the end of the nebulized therapy, in order to support a "GO / NO GO" decision towards a phase III trial of nebulized caspofungin in those patients.
The 3 groups in the trial
- Part 2 - randomized study (group 1)Treatment being tested
Conventional systemic antifungal treatment (systemic co-trimoxazole or systemic second line anti-Pneumocystis salvage therapy) + aerosols of echinocandin (50 mg caspofungin) during one to seven days (according to the regimen retained from the results of part 1 from day-1 to d-7) using vibrating mesh nebulization device
Treatment: Caspofungin Acetate 50 MG
- Part 2 - randomized study (group 2)Placebo, for comparison
Control group: (in part 2 only) Conventional systemic antifungal treatment (systemic co-trimoxazole or systemic second-line anti-Pneumocystis salvage therapy) + aerosols of placebo (0.9% saline in a volume equivalent to the experimental group) during one to seven days (according to the regimen retained from part 1 results) using vibrating mesh nebulization device
Treatment: Physiologic saline
- Part 1 - open studyTreatment being tested
open-label non-randomized group, with ascending scheme regarding the dose and rhythm of administration over one week, depending on the tolerance, and closely monitored in ICU to ensure that caspofungin is well tolerated via the inhaled route, and to provide data supporting the proposed administration scheme for part 2. * the first two patients (included one by one) will receive two aerosols (5 mg) during the first week, four days apart on d-1 and d-5 (level 1); * the third and fourth will receive two aerosols (15 mg) during the first week, four days apart on d-1 and d-5 (level 2); * the fifth and sixth will receive two aerosols (50 mg) during the first week, four days apart on d-1 and d-5 (level 3); * the seventh and eighth patients will receive four aerosols (50 mg) two days apart during one week, at d-1, then d-3, d-5 and d-7 (level 4); * the last two patients will have daily aerosols during the first week, from d-1 to d-7 (level 5)
Treatment: Caspofungin Acetate 50 MG
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Phase I/II Safety lead-in Randomized Blind Placebo-controlled Clinical Trial: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia in Adjunction of Conventional Systemic Antifungal Therapy
- Publications
- Pneumocystis jiroveci : still troublesome to diagnose and treat.Current opinion in infectious diseases, 2025
- Record updated
- 9 October 2026